Hepion Pharmaceuticals terminates merger agreement with Pharma Two B

Hepion Pharmaceuticals (HEPA) has entered into a termination agreement with Pharma Two B which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024. Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the agreement. Hepion also announced that its previously announced special meeting of its stockholders scheduled for December 12, 2024 has been cancelled and that it has withdrawn from consideration by its stockholders the proposals set forth in the Company’s Definitive Proxy Statement on Form F-4 filed with the U.S. Securities and Exchange Commission on November 8, 2024.